Benzinga | Dec 14, 2020 08:16AM EST

Credit Suisse Downgrades Alexion Pharmaceuticals to Neutral, Raises Price Target to $194

Credit Suisse downgrades Alexion Pharmaceuticals (NASDAQ:ALXN) from Outperform to Neutral and raises the price target from $147 to $194.